Switching α-glucosidase inhibitors to miglitol reduced glucose fluctuations and circulating cardiovascular disease risk factors in type 2 diabetic Japanese patients.
Drugs R & D
14
3
177
184
https://pubmed.ncbi.nlm.nih.gov/25079671/